224 Outcomes of stage IV melanoma in the era of immunotherapy: a national cancer database (NCDB) analysis

224 Outcomes of stage IV melanoma in the era of immunotherapy: a national cancer database (NCDB) analysis

Bibliographic Details
Main Authors:	Wei Wei, Brian Gastman, Pauline Funchain, Tamara Sussman
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016
by: Wei Wei, et al.
Published: (2022-08-01)

Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al
by: Justin T Moyers, et al.
Published: (2022-12-01)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
by: Lillian Sun, et al.
Published: (2018-05-01)

197 Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect?
by: Brian Gastman, et al.
Published: (2020-11-01)

Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB).
by: Taylor D Ottesen, et al.
Published: (2022-01-01)

Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis
by: Nadeem Bilani MD, et al.
Published: (2020-12-01)

NCDB Analysis of Melanoma 2004–2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval
by: Sunny R. K. Singh, et al.
Published: (2021-03-01)

Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study
by: Clare M. Wieland, et al.
Published: (2024-04-01)

Impact of treatment modality on overall survival (OS) in localized ductal prostate adenocarcinoma (PCa): A national cancer database (NCDB) analysis
by: C. Bronkema, et al.
Published: (2020-07-01)

Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report
by: Tapas Ranjan Behera, et al.
Published: (2022-06-01)

Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
by: Lisa Gonçalves, et al.
Published: (2023-08-01)

Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer—A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
by: Louisa Bolm, et al.
Published: (2022-02-01)

Factors influencing receipt and time to treatment of immunotherapy relative to chemotherapy in stage III and stage IV melanoma
by: Gurman S. Dhaliwal, et al.
Published: (2024-01-01)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
by: Stephanie A. Blankenstein, et al.
Published: (2020-05-01)

Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis
by: Liling Zhu, et al.
Published: (2019-01-01)

Rates of margin positive resection with breast conservation for invasive breast cancer using the NCDB
by: Hotsinpiller WJ, et al.
Published: (2021-12-01)

Immunotherapy in the Precision Medicine Era: Melanoma and Beyond.
by: Mack Y Su, et al.
Published: (2016-12-01)

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
by: Teresa Amaral, et al.
Published: (2020-04-01)

The cost of unresectable stage III or stage IV melanoma in Italy
by: Maio Michele, et al.
Published: (2012-11-01)

Abstract QS2: Influence of Race, Income, Insurance and Education in Rate of Breast Reconstruction: an NCDB 2004–15 Analysis
by: David J. Restrepo, MD, et al.
Published: (2019-04-01)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
by: Pawel Teterycz, et al.
Published: (2020-10-01)

Lack of Racial Survival Differences in Metastatic Prostate Cancer in National Cancer Data Base (NCDB): A Different Finding Compared to Non-metastatic Disease
by: Toms Vengaloor Thomas, et al.
Published: (2020-09-01)

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics
by: Lukas W Pfannenstiel, et al.
Published: (2024-04-01)

The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis
by: Binhao Huang, et al.
Published: (2021-12-01)

591 Survival rates in Stage IV melanoma patients treated with radiation and immunotherapy differ depending on age and radiation treatment site
by: Matthew Peach, et al.
Published: (2021-11-01)

Legal status of women in the Sassanid’s Era (224–651 AD)
by: Mahmoud Emami Namin
Published: (2018-01-01)

Abstract 176: ICG-fluorescence Imaging With Lymphoscintigraphy For Sentinel Node Biopsy In Melanoma: Reducing The False Negative Rate
by: Rebecca Knackstedt, et al.
Published: (2020-04-01)

Immunotherapy utilization in stage IIIA melanoma: less may be more
by: Alexander E. Frey, et al.
Published: (2024-02-01)

Immunotherapy of melanoma.
by: Smith, C, et al.
Published: (2001)

IMMUNOTHERAPY FOR MELANOMA
by: E. A. Borobova, et al.
Published: (2017-09-01)

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
by: Paul Wong, et al.
Published: (2024-03-01)

Changes in healthcare costs and survival in the era of immunotherapy and targeted systemic therapy for melanoma.
by: Paul Nguyen, et al.
Published: (2022-08-01)

Melanoma body site distribution: Germline genetics may have a lesser role
by: Lorvens Decosma, BS, et al.
Published: (2023-06-01)

Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy
by: Felix Peisen, et al.
Published: (2022-06-01)

A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma
by: Konstantin Nikolaou, et al.
Published: (2021-11-01)

Limb‐sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high‐grade, extremity soft‐tissue sarcoma from the NCDB and SEER
by: Stephen J. Ramey, et al.
Published: (2018-09-01)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
by: Ze-Long Liu, et al.
Published: (2020-08-01)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
by: Ann Livingstone, et al.
Published: (2021-09-01)

Clinical predictors of survival in real world practice in stage IV melanoma
by: Hsien‐Pang Hu, et al.
Published: (2023-02-01)

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.
by: Irene Orlow, et al.
Published: (2023-01-01)